Investors will want to pay attention to what Assembly Biosciences, CymaBay Therapeutics, and Madrigal Pharmaceuticals say about their most promising candidate therapies.
News & Analysis: Madrigal Pharmaceuticals, Inc.
Which of these NASH-oriented biotechs is the better buy?
A new year and reasons to remain hopeful for these three biotechs are around the corner.
Impressive results from a potential competitor took the shine off this biotech's experimental NASH treatment.
Madrigal's stock continued to cool off last month, but another rally could be close at hand.
Which stock wins in a matchup between these biotechs hoping for success with promising NASH drugs?
Solid phase 2 data has investors excited about the biotech's future.
Here's why these three biotechs could come out ahead in the race to tackle a leading cause of liver failure.
The company is apparently demanding top dollar in a buyout scenario.
Find out what's pushing shares of these biotechs through the roof.